Alto Neuroscience, Inc. (NYSE:ANRO) to Post Q3 2024 Earnings of ($0.64) Per Share, William Blair Forecasts

Alto Neuroscience, Inc. (NYSE:ANRO) – Investment analysts at William Blair raised their Q3 2024 earnings per share (EPS) estimates for shares of Alto Neuroscience in a report issued on Tuesday, August 13th. William Blair analyst M. Minter now expects that the company will post earnings of ($0.64) per share for the quarter, up from their prior forecast of ($0.89). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.93) per share. William Blair also issued estimates for Alto Neuroscience’s Q4 2024 earnings at ($0.76) EPS, FY2024 earnings at ($2.73) EPS, Q1 2025 earnings at ($0.66) EPS, Q2 2025 earnings at ($0.67) EPS, Q3 2025 earnings at ($0.70) EPS, Q4 2025 earnings at ($0.73) EPS, FY2025 earnings at ($2.77) EPS, FY2026 earnings at ($2.48) EPS, FY2027 earnings at ($2.43) EPS and FY2028 earnings at ($3.16) EPS.

Separately, Rodman & Renshaw assumed coverage on Alto Neuroscience in a report on Friday, June 21st. They set a “buy” rating and a $43.00 price target for the company. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, Alto Neuroscience currently has a consensus rating of “Buy” and an average target price of $35.00.

Alto Neuroscience Stock Down 0.2 %

Alto Neuroscience stock opened at $9.36 on Friday. The firm has a fifty day simple moving average of $11.76. Alto Neuroscience has a 1-year low of $7.91 and a 1-year high of $24.00. The company has a debt-to-equity ratio of 0.05, a quick ratio of 26.02 and a current ratio of 26.02.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Tuesday, August 13th. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.07.

Insider Activity at Alto Neuroscience

In other Alto Neuroscience news, insider Adam Savitz purchased 12,069 shares of the company’s stock in a transaction that occurred on Tuesday, July 9th. The shares were bought at an average cost of $12.60 per share, for a total transaction of $152,069.40. Following the purchase, the insider now owns 36,920 shares of the company’s stock, valued at approximately $465,192. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Institutional Investors Weigh In On Alto Neuroscience

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD bought a new stake in Alto Neuroscience during the first quarter valued at approximately $9,788,000. Vanguard Group Inc. bought a new stake in shares of Alto Neuroscience during the 1st quarter worth $8,233,000. Jennison Associates LLC purchased a new position in Alto Neuroscience in the first quarter worth $7,039,000. Zimmer Partners LP purchased a new position in Alto Neuroscience in the first quarter worth $1,151,000. Finally, RA Capital Management L.P. bought a new position in Alto Neuroscience in the first quarter valued at $21,267,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.